Literature DB >> 31320066

Advances in chitosan-based nanoparticles for oncotherapy.

Enhui Zhang1, Ronge Xing2, Song Liu1, Yukun Qin1, Kecheng Li1, Pengcheng Li3.   

Abstract

Chitosan has attracted considerable attention as an anti-tumor drug carrier material in recent years, which is due to its biocompatibility and biodegradability, as well as the simple and mild preparing techniques of drug-loaded nanoparticles. Chitosan-based nanoparticles can deliver various anti-tumor agents to specific tumor tissues by passive and active targeting mechanisms, including traditional chemotherapeutic agents, DNA or siRNA, proteins, photosensitizers and so on. In this review, we summarized the factors affecting the anti-tumor efficacy of chitosan-based nanoparticles, to aid exploring the function-structure relationship. The recent studies on chitosan-based nanoparticles for oncotherapy were highlighted, including their structures, properties and pharmacological effects. Finally, we offered our perspectives on the challenges and future development of this area.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anti-tumor; Chitosan; Drug delivery; Nanoparticle

Year:  2019        PMID: 31320066     DOI: 10.1016/j.carbpol.2019.115004

Source DB:  PubMed          Journal:  Carbohydr Polym        ISSN: 0144-8617            Impact factor:   9.381


  31 in total

1.  Counterion of Chitosan Influences Thermodynamics of Association of siRNA with a Chitosan-Based siRNA Carrier.

Authors:  Christelle Zandanel; Magali Noiray; Christine Vauthier
Journal:  Pharm Res       Date:  2020-01-02       Impact factor: 4.200

2.  Water-Soluble Chitosan Conjugated DOTA-Bombesin Peptide Capped Gold Nanoparticles as a Targeted Therapeutic Agent for Prostate Cancer.

Authors:  Theeranan Tangthong; Thananchai Piroonpan; Velaphi C Thipe; Menka Khoobchandani; Kavita Katti; Kattesh V Katti; Wanvimol Pasanphan
Journal:  Nanotechnol Sci Appl       Date:  2021-03-18

3.  A Mansonone Derivative Coupled with Monoclonal Antibody 4D5-Modified Chitosan Inhibit AKR1C3 to Treat Castration-Resistant Prostate Cancer.

Authors:  Meng Zhou; Xiaoyu Wang; Jie Xia; Yating Cheng; Lichun Xiao; Yu Bei; Jianzhong Tang; Yadong Huang; Qi Xiang; Shiliang Huang
Journal:  Int J Nanomedicine       Date:  2020-05-01

Review 4.  Chitosan-Based Nanoparticles of Targeted Drug Delivery System in Breast Cancer Treatment.

Authors:  Yedi Herdiana; Nasrul Wathoni; Shaharum Shamsuddin; I Made Joni; Muchtaridi Muchtaridi
Journal:  Polymers (Basel)       Date:  2021-05-24       Impact factor: 4.329

5.  Paclitaxel-Loaded Folate-Targeted Albumin-Alginate Nanoparticles Crosslinked with Ethylenediamine. Synthesis and In Vitro Characterization.

Authors:  Ana María Martínez-Relimpio; Marta Benito; Elena Pérez-Izquierdo; César Teijón; Rosa María Olmo; María Dolores Blanco
Journal:  Polymers (Basel)       Date:  2021-06-24       Impact factor: 4.329

Review 6.  Orally Administrable Therapeutic Nanoparticles for the Treatment of Colorectal Cancer.

Authors:  Kangkang Ying; Bingjun Bai; Xing Gao; Yuzi Xu; Hangxiang Wang; Binbin Xie
Journal:  Front Bioeng Biotechnol       Date:  2021-07-07

7.  Multi-Bit Biomemory Based on Chitosan: Graphene Oxide Nanocomposite with Wrinkled Surface.

Authors:  Lei Li; Guangming Li
Journal:  Micromachines (Basel)       Date:  2020-06-10       Impact factor: 2.891

Review 8.  Chitosan Derivatives and Their Application in Biomedicine.

Authors:  Wenqian Wang; Qiuyu Meng; Qi Li; Jinbao Liu; Mo Zhou; Zheng Jin; Kai Zhao
Journal:  Int J Mol Sci       Date:  2020-01-12       Impact factor: 5.923

Review 9.  Targeting Tumor Endothelial Cells with Nanoparticles.

Authors:  Yu Sakurai; Hidetaka Akita; Hideyoshi Harashima
Journal:  Int J Mol Sci       Date:  2019-11-20       Impact factor: 5.923

10.  Synthesis of surfactant-modified ZIF-8 with controllable microstructures and their drug loading and sustained release behaviour.

Authors:  Xinyu Xu; Ye Liu; Zhaoming Guo; Xue-Zhi Song; Xiuyu Qi; Zideng Dai; Zhenquan Tan
Journal:  IET Nanobiotechnol       Date:  2020-09       Impact factor: 1.847

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.